Expanding indications for transcatheter aortic valve replacement
dc.creator | Maluenda, Gabriel | |
dc.creator | Dvir, Danny | |
dc.date.accessioned | 2019-03-15T16:06:39Z | |
dc.date.available | 2019-03-15T16:06:39Z | |
dc.date.created | 2019-03-15T16:06:39Z | |
dc.date.issued | 2014 | |
dc.identifier | Expert Review of Cardiovascular Therapy, Volumen 12, Issue 6, 2018, Pages 693-702 | |
dc.identifier | 17448344 | |
dc.identifier | 14779072 | |
dc.identifier | 10.1586/14779072.2014.916615 | |
dc.identifier | https://repositorio.uchile.cl/handle/2250/166174 | |
dc.description.abstract | Transcatheter aortic valve replacement (TAVR) has emerged as an accepted indication for non-operable patients with severe symptomatic native aortic valve stenosis (AS) and as a reasonable alternative for high-risk surgical AS patients. Nonetheless, the safety and efficacy of performing TAVR in several other potential indications are yet unclear. In the present manuscript the authors review the current evidence supporting TAVR for other potential indications than the typical high-risk/non-operable AS patients, providing updated results of the main clinical trials and registries exploring these particular indications. Finally, the authors provide practical recommendations for TAVR in each of these conditions. © 2014 Informa UK, Ltd. | |
dc.language | en | |
dc.publisher | Expert Reviews Ltd. | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ | |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Chile | |
dc.source | Expert Review of Cardiovascular Therapy | |
dc.subject | Aortic regurgitation | |
dc.subject | Aortic stenosis | |
dc.subject | Bicuspid aortic stenosis | |
dc.subject | Moderate risk | |
dc.subject | Transcatheter aortic valve replacement | |
dc.subject | Valve-in-valve | |
dc.title | Expanding indications for transcatheter aortic valve replacement | |
dc.type | Artículo de revista |